Biostage Inc (BSTG) Given a $3.00 Price Target by Maxim Group Analysts
Biostage Inc (NASDAQ:BSTG) has been assigned a $3.00 target price by stock analysts at Maxim Group in a research note issued on Friday. The brokerage presently has a a “buy” rating on the stock. Maxim Group’s price target points to a potential upside of 172.73% from the stock’s previous close.
Shares of Biostage (NASDAQ:BSTG) traded down 13.455% during trading on Friday, reaching $0.952. 349,798 shares of the company’s stock were exchanged. The stock’s 50 day moving average price is $1.05 and its 200-day moving average price is $1.36. Biostage has a 52-week low of $0.53 and a 52-week high of $3.47. The stock’s market cap is $16.29 million.
Biostage (NASDAQ:BSTG) last issued its earnings results on Thursday, August 11th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.04. On average, equities research analysts forecast that Biostage will post ($0.86) EPS for the current year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/07/biostage-inc-bstg-given-a-3-00-price-target-by-maxim-group-analysts.html
Biostage, Inc, formerly Harvard Apparatus Regenerative Technology, Inc, is a biotechnology company. The Company is engaged in developing bioengineered organ implants based on its Cellframe technology. Its Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient’s own cells.
Receive News & Ratings for Biostage Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostage Inc and related companies with MarketBeat.com's FREE daily email newsletter.